![\"essner\"](\"http:\/\/s.wsj.net\/public\/resources\/images\/OB-IC000_essner_D_20100408100652.jpg\")
We can fill in the another line on that always-popular list — Where Are the Ex-Pharma CEOs Now?<\/p>\nWe can fill in the another line on that always-popular list — Where Are the Ex-Pharma CEOs Now?<\/p>\n
This time, the career move involves Bob Essner, who was CEO of Wyeth between 2001 and the end of 2007 and retired a few months later as chairman of Wyeth (now part of Pfizer) at age 60. Today, private-equity group Carlyle Group said that Essner (pictured in 2004) will become a senior adviser on the firm’s health-care investments.<\/p>\n
Carlyle Group is a behemoth in private-equity circles and has plunked down money for a bevvy of health-care investments over the years (here’s a rundown<\/a> from its Web site). Essner will help manage businesses like U.S. nursing-home operator HCR Manor Care and Qualicaps Group, a Japanese capsule manufacturer, the WSJ<\/a> says.<\/p>\n Essner told the Health Blog<\/a> earlier this year that the pharma industry today “is radically different than what I grew up in [it], in the \u009280s and early \u009290s.\u0094 He added: \u0093It\u0092s a much tougher environment. It\u0092s in some ways a more punishing one, more cost-conscious and productivity-oriented.\u0094<\/p>\n As Wyeth’s CEO, he led the company as it coped with the litigation fallout<\/a> over a diet-drug cocktail known as fen-phen that ended up costing tens of billions of dollars. See more on his ups and downs at Wyeth, see here<\/a> and here<\/a>. Of late, Essner has been teaching at the Columbia Business School and is lead director on the board of Massachusetts Mutual Life Insurance<\/a>.<\/p>\n Ex-CEO Fred Hassan<\/a> of Schering-Plough (now part of Merck) has been working with private-equity firm Warburg Pincus and last month was named chairman of Bausch & Lomb, a Warburg holding. Soon to join the ex-CEO list is Bristol-Myer Squibb’s Jim Cornelius<\/a>, who will remain the company’s chairman. <\/p>\n Buyout bonus:<\/strong> Clayton Dubilier & Rice announced ex-CEO A.G. Lafley of Procter & Gamble is joining that private-equity firm as a special partner. Here’s the WSJ article<\/a>.<\/p>\n Photo: Bloomberg News<\/em><\/p>\n We can fill in the another line on that always-popular list — Where Are the Ex-Pharma CEOs Now? This time, the career move involves Bob Essner, who was CEO of Wyeth between 2001 and the end of 2007 and retired a few months later as chairman of Wyeth (now part of Pfizer) at age 60. […]<\/p>\n","protected":false},"author":792,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-520388","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/520388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/792"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=520388"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/520388\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=520388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=520388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=520388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/img><\/a>
\n<\/img><\/a><\/p>\n
\n<\/img><\/a>
<\/img><\/a>
<\/img><\/a>
<\/img><\/a>
<\/img><\/a>\n<\/div>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"